Which statement about USP 800 requirements for NIOSH-listed drugs is correct?

Which statement about USP 800 requirements for NIOSH-listed drugs is correct?

• A. Final dosage forms of compounded HD preps that do not require manipulation
• B. All HDs regardless of manipulation
• C. Over-the-counter HD products
• D. Any HD API

Answer: (D)

US P 800 governs protection against exposure to hazardous drugs that appear on the NIOSH list. The crucial point is that the hazard is tied to the drug’s active pharmaceutical ingredient, not to a specific dosage form or whether manipulation is being done at the moment. Therefore, handling any hazardous drug API requires the same exposure controls, regardless of whether you’re working with a finished product or a compounded preparation, and even if the product is over-the-counter. That’s why the correct statement is that any HD API triggers USP 800 requirements. The other options are narrower or misaligned with how USP 800 is scoped. Limiting requirements to final dosage forms that don’t require manipulation misses scenarios where the API is hazardous and exposure could occur. Saying all HDs must be managed regardless of manipulation is broader in intent but isn’t the API-focused framing USP 800 uses. Over-the-counter HD products aren’t exempt just because they’re OTC, since the hazard comes from the API.

US P 800 governs protection against exposure to hazardous drugs that appear on the NIOSH list. The crucial point is that the hazard is tied to the drug’s active pharmaceutical ingredient, not to a specific dosage form or whether manipulation is being done at the moment. Therefore, handling any hazardous drug API requires the same exposure controls, regardless of whether you’re working with a finished product or a compounded preparation, and even if the product is over-the-counter. That’s why the correct statement is that any HD API triggers USP 800 requirements.

The other options are narrower or misaligned with how USP 800 is scoped. Limiting requirements to final dosage forms that don’t require manipulation misses scenarios where the API is hazardous and exposure could occur. Saying all HDs must be managed regardless of manipulation is broader in intent but isn’t the API-focused framing USP 800 uses. Over-the-counter HD products aren’t exempt just because they’re OTC, since the hazard comes from the API.